1. Home
  2. CP vs REGN Comparison

CP vs REGN Comparison

Compare CP & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CP

Canadian Pacific Kansas City Limited

N/A

Current Price

$83.25

Market Cap

66.7B

Sector

Industrials

ML Signal

N/A

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

N/A

Current Price

$775.09

Market Cap

79.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CP
REGN
Founded
1881
1988
Country
Canada
United States
Employees
N/A
N/A
Industry
Railroads
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.7B
79.4B
IPO Year
2000
1995

Fundamental Metrics

Financial Performance
Metric
CP
REGN
Price
$83.25
$775.09
Analyst Decision
Buy
Buy
Analyst Count
10
24
Target Price
$92.10
$819.54
AVG Volume (30 Days)
2.6M
599.7K
Earning Date
04-29-2026
04-16-2026
Dividend Yield
0.75%
0.49%
EPS Growth
13.32
8.19
EPS
4.51
41.48
Revenue
$15,078,000,000.00
$5,872,227,000.00
Revenue This Year
$8.21
$11.69
Revenue Next Year
$6.32
$10.06
P/E Ratio
$18.61
$18.65
Revenue Growth
3.66
20.82
52 Week Low
$66.49
$476.49
52 Week High
$89.42
$821.11

Technical Indicators

Market Signals
Indicator
CP
REGN
Relative Strength Index (RSI) 50.88 50.28
Support Level $73.31 $740.39
Resistance Level $89.42 $788.69
Average True Range (ATR) 1.92 20.92
MACD -0.80 -1.67
Stochastic Oscillator 21.04 58.46

Price Performance

Historical Comparison
CP
REGN

About CP Canadian Pacific Kansas City Limited

Canadian Pacific Kansas City is a Class I railroad operating on track that spans across most of Canada and into parts of the Midwestern and Northeastern United States. Following the April 2023 Kansas City Southern merger, CPKC operates new single-linehaul services from Canada and the Upper Midwest down through Texas, the Gulf of Mexico, and into Mexico. It also hauls cross-border and intra-Mexico freight via operating concessions on more than 3,000 miles of rail in Mexico. CPKC hauls shipments of grain, intermodal containers, energy products (like crude and frac sand), chemicals, plastics, coal, fertilizer and potash, automotive products, and a diverse mix of other merchandise.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: